Enanta Pharmaceuticals, Inc.
ENTA
Last
$12.50
Day
+3.3%
1y
+5.6%
5y
-79.9%
52w
-29.4%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1636d
EMA 21
12.57
EMA 50
12.88
EMA 200
12.81
20d high
-10.0%
5y high
-88.1%
5y range
8th
Positions held
Your positionsENTA isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-23
Hold
avoid
Signal
Strong Sell
Target
$13.18
Stop
$11.20
Stop distance
10.4%
Target vs last
+5.4%
Fundamentals
| Market cap | $352.42M | Enterprise value | $344.95M | Trailing P/E | — | Forward P/E | -5.10 |
| PEG | — | Price / book | 3.49 | Beta | 0.96 | Dividend yield | 0.00% |
| Revenue growth | -21.6% | Earnings growth | — | Gross margin | 100.0% | Operating margin | -120.0% |
| Profit margin | -96.9% | ROE | -70.1% | ROA | -12.3% | Debt / equity | 1.80 |
| Current ratio | 3.76 | Free cash flow | -$22.66M | Analyst recommendation | none | Mean target | $21.83 |
| 52w high | $17.15 | 52w low | $10.20 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $14.4M | $17.2M | $18.6M | $15.1M | $18.3M |
| Op margin | -120.0% | -69.1% | -60.5% | -121.6% | -103.2% |
| Net income | -$19.5M | -$13.1M | -$11.9M | -$18.7M | -$18.3M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$17.2M | -$11.9M | -$11.3M | -$18.4M | -$18.9M |
- Revenue -16% vs prior quarter ($14M vs $17M).
- Operating margin compressed to -120%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $65.3M | $67.6M | $79.2M | $86.2M |
| Op margin | -130.7% | -179.9% | -173.2% | -143.7% |
| Net income | -$81.9M | -$116M | -$134M | -$122M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$85.3M | -$122M | -$137M | -$124M |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-01 · Enanta Pharmaceuticals to Participate in September Investor Conferences
2026-08-10 · Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates
2026-08-10 · Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot
2026-08-10 · Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
2026-07-21 · Nuvation Bio (NUVB) Soars 7.9%: Is Further Upside Left in the Stock?
Price (daily)
Full chart · RSI · MACD · patternsENTA · daily-2.6% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin